Kiora Pharmaceuticals’ (KPRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a research note issued to investors on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Kiora Pharmaceuticals Stock Up 2.0 %

Shares of KPRX stock opened at $3.08 on Friday. The company has a 50 day moving average price of $3.46 and a 200-day moving average price of $3.48. Kiora Pharmaceuticals has a 52 week low of $2.91 and a 52 week high of $6.30. The firm has a market capitalization of $9.24 million, a PE ratio of 2.96 and a beta of -0.46.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its earnings results on Tuesday, March 25th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.40). The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.75 million. Analysts anticipate that Kiora Pharmaceuticals will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC grew its holdings in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 200,221 shares of the company’s stock after acquiring an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.